Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.54 |
| ▸ | CA2 | P00918 | 12/20 | 0.54 |
| ▸ | CA12 | O43570 | 8/20 | 0.54 |
| ▸ | CA9 | Q16790 | 8/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16845445 | 0.85 | CA2 (0.44) | CA1CA2CA12CA9CHRNA7 | |
| SCHEMBL16819975 | 0.85 | CA2 (0.44) | CA1CA2CA12CA9CHRNA7 | |
| SCHEMBL18919029 | 0.85 | CA2 (0.44) | CA1CA2CA12CA9CHRNA7 | |
| SCHEMBL16820020 | 0.83 | CA1 (0.54) | CA1CA2CA12CA9CA4 | |
| SCHEMBL16845469 | 0.83 | CA1 (0.54) | CA1CA2CA12CA9CA4 | |
| SCHEMBL16845385 | 0.82 | POLB (0.39) | CA1CA2CA12CA9CHRNA7 | |
| SCHEMBL18919030 | 0.82 | POLB (0.39) | CA1CA2CA12CA9CHRNA7 | |
| SCHEMBL18919022 | 0.81 | CA2 (0.45) | CA1CA2CA12CA9CYP1A2 | |
| SCHEMBL16845435 | 0.81 | SOS1 (0.51) | CA1CA2CA12CA9CA4 | |
| SCHEMBL16820018 | 0.81 | SOS1 (0.51) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158628-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158628-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I | CHRNA7, CHRNA5, CHRNA6 | CA1 1704/4885CA2 2747/4885CA12 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.